title: A case of cicatricial alopecia associated with erlotinib.
abstract: Erlotinib is a small-molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Erlotinib has been used primarily to treat non-small cell lung cancer. In addition to its role in tumor cells, EGFR is also an important regulator of growth and differentiation in the skin and hair. Therefore, EGFR-TKIs have been associated with a number of cutaneous side effects including follicular acneiform eruptions, cutaneous xerosis, chronic paronychia, desquamation, seborrheic dermatitis, and hair texture changes. Herein, we report a rare case of a 61-year-old woman who was treated with erlotinib and experienced cicatricial alopecia.
authors.affiliation: Department of Dermatology, Inha University School of Medicine, Incheon, Korea.
authors.forename: Bo Hee
authors.initials: BH
authors.lastname: Yang
authors.forename: Chan Yl
authors.initials: CY
authors.lastname: Bang
authors.forename: Ji Won
authors.initials: JW
authors.lastname: Byun
authors.forename: Sung Hyub
authors.initials: SH
authors.lastname: Han
authors.forename: Hee Jin
authors.initials: HJ
authors.lastname: Song
authors.forename: Seung Gyun
authors.initials: SG
authors.lastname: In
authors.forename: Jeong Hyun
authors.initials: JH
authors.lastname: Shin
authors.forename: Gwang Seong
authors.initials: GS
authors.lastname: Choi